Portfolio company
ProFactor Pharma
United Kingdom
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This company develops recombinant Factor VIII to treat haemophilia A in patients who currently lack access to affordable medication.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Enzyre
This company develops a portable diagnostic device for haemophilia patients to monitor blood coagulation status and manage treatment from home.
HemaB
Hemab Therapeutics develops prophylactic antibody therapies for patients with rare bleeding and thrombotic disorders including Glanzmann thrombasthenia and Factor VII deficiency.
BioFactor Therapeutics AB
This pharmaceutical developer creates recombinant protein therapies for patients with metabolic and endocrine disorders.
VarmX
This biotech company develops recombinant blood clotting factors to treat patients with severe bleeding or requiring urgent surgery while taking oral anticoagulants.
Protalix
This company develops and produces plant-based recombinant therapeutic proteins to treat patients with rare diseases, including Fabry and Gaucher disease.
Be Biopharma
This company develops engineered B cell medicines to treat patients with hemophilia B, genetic diseases, and cancer.
Proteon Therapeutics
This company develops pharmaceuticals to improve blood flow and vascular access for patients with kidney and vascular diseases.
Coagulant Therapeutics
This company develops medicines to treat acute bleeding conditions, such as postpartum haemorrhage and traumatic brain injury, for patients with urgent medical needs.